{"id":"W4407095407","doi":"10.1016/s1470-2045(24)00682-x","title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"Janssen Alzheimer Immunotherapy Research And Development; Janssen Research and Development","keywords":"Ibrutinib; Venetoclax; Mantle cell lymphoma; Medicine; Placebo; Refractory (planetary science); Internal medicine; Oncology; Double blind; Phases of clinical research; Lymphoma; Clinical trial; Leukemia; Pathology; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00331887,0.0003904726,0.002184671,0.0003823589,0.0001715819,0.00004182948,0.0007015179,0.0003556396,0.0004436755],"category_scores_gemma":[0.0009424503,0.0002394992,0.0002033016,0.0007303222,0.0002755905,0.00005830247,0.000312845,0.0006921642,0.000250358],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.02437306,"about_ca_system_score_gemma":0.02201064,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001310099,"about_ca_topic_score_gemma":0.001476129,"domain_scores_codex":[0.9953398,0.001278445,0.00108186,0.0006656204,0.0005454402,0.001088846],"domain_scores_gemma":[0.9938741,0.004149743,0.000316226,0.001308868,0.0001489404,0.0002021169],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9768429,0.004505645,0.0002179001,0.0002684063,0.0004795261,0.002103745,0.00347049,0.0002987785,0.0005323575,0.00006991705,0.005349023,0.005861267],"study_design_scores_gemma":[0.9431031,0.00304977,0.0001166499,0.0001476409,0.0005352228,0.0001034571,0.002604193,0.03179467,0.0005366368,0.0000386129,0.01775754,0.0002125124],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9508475,0.0009797071,0.00003482888,0.001760715,0.0005943044,0.01237074,0.000008761831,0.0001127646,0.03329064],"genre_scores_gemma":[0.9820353,0.0003004989,0.0001764777,0.001329866,0.0005118739,0.002153464,0.00002332716,0.00004941631,0.01341974],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03373985,"threshold_uncertainty_score":0.9835337,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06933435470979207,"score_gpt":0.4133611366597585,"score_spread":0.3440267819499665,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}